-

Ionis to host expert panel discussion on sHTG

– Webinar scheduled for Monday, April 14 at 11:00 a.m. ET –

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet medical needs associated with severe hypertriglyceridemia (sHTG). Key thought leaders in lipidology, cardiology and endocrinology will join Sam Tsimikas, M.D., senior vice president, global cardiovascular development, Ionis, for a live discussion followed by a brief Q&A session. Panelists include:

  • Seth Baum, M.D., MASPC, FACC, FAHA, FNLA chief medical officer, Flourish Research and clinical affiliate professor of cardiology, Florida Atlantic University
  • Alan S. Brown, M.D., FNLA, director, Lipid Clinic, Advocate Lutheran General Hospital and adjunct clinical professor of medicine, Rosalind Franklin University of Medicine and Science
  • Savitha Subramanian, M.D., medical director, Lipid Clinic and professor of medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington Medical Center

The webinar may be accessed at https://ir.ionis.com/events. A replay will be available for a limited time.

About Ionis Pharmaceuticals, Inc.

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

Contacts

Ionis Investor Contact:
D. Wade Walke, Ph.D. – IR@ionis.com – 760-603-2331

Ionis Media Contact:
Hayley Soffer – media@ionis.com – 760-603-4679

Industry:

Ionis Pharmaceuticals, Inc.

NASDAQ:IONS
Release Versions
English

Contacts

Ionis Investor Contact:
D. Wade Walke, Ph.D. – IR@ionis.com – 760-603-2331

Ionis Media Contact:
Hayley Soffer – media@ionis.com – 760-603-4679

More News From Ionis Pharmaceuticals, Inc.

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to zilganersen for the treatment of Alexander disease (AxD), a rare, progressive and often fatal neurological condition. Over time, it can lead to loss of mobility and independence, along with difficulties walking, speaking, swallowing and breathing. There are currently no approved disease-modifying treatments...

Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olezarsen as an adjunct to diet to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (sHTG) (TG greater than or equal to 500 mg/dL). Breakthrough Therapy designation is intended to expedite the review of medicines that treat a serious or life-threatening condition and have shown pre...

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of DAWNZERA™ (donidalorsen) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The positive opinion is now referred to the European Commission (EC) for an...
Back to Newsroom